ROXATIDINE

DRUG3 trials

Sponsors

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd., Canadian Network for Observational Drug Effect Studies, CNODES

Conditions

Advanced or Metastatic Non-small Cell Lung CancerCommunity-acquired PneumoniaGastroesophageal Reflux Disease (GERD)Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

Phase 2

A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer

Active, not recruitingCTIS2023-507270-41-00

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.Advanced or Metastatic Non-small Cell Lung Cancer

Start: 2024-11-22Target: 46Updated: 2025-07-29

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors Who are Refractory to Available Standard Therapies

CompletedCTIS2023-508700-38-00

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

End: 2024-12-10Target: 31Updated: 2024-06-20

Unknown Phase

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

CompletedNCT02555852

Canadian Network for Observational Drug Effect Studies, CNODESCommunity-acquired Pneumonia, Gastroesophageal Reflux Disease (GERD)

Start: 2011-09-30End: 2012-02-29Updated: 2015-09-22